CXCR6 <sup>+</sup> T Cells Drive Immune Checkpoint Inhibitor Myocarditis
Our findings suggest that ICI myocarditis is driven by an expansion of CXCR6<sup>+</sup> T cells and identifies CXCR6 as a putative therapeutic target for this highly morbid condition.
Authors
- Kory J. Lavine (ORCID: https://orcid.org/0000-0003-1948-9945)
- Javid J. Moslehi (ORCID: https://orcid.org/0000-0001-5443-4312)
- Amir Z. Munir (ORCID: https://orcid.org/0009-0009-3512-5851)
- Priyanka Manandhar (ORCID: https://orcid.org/0000-0003-2868-5286)
- Richard A. Baylis (ORCID: https://orcid.org/0000-0001-7040-7920)
- Lei Hou (ORCID: https://orcid.org/0000-0002-5636-4028)
- Justin Micah Balko (ORCID: https://orcid.org/0000-0002-4263-5974)
- Joe-elie Salem
- Alan Gutierrez (ORCID: https://orcid.org/0000-0001-9129-243X)
- Andrew H. Lichtman
- C M Krawiec
- Anya C. Shyani
- Pan Ma
- Eileen Remold-O’Donnell
- Paul Gougis
- Juan Qin
Institutions
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Inserm (FR)
- Washington University in St. Louis (US)
- Cardiovascular Institute of the South (US)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Clinical Investigation Center Plurithematic Tours (FR)
- Pitié-Salpêtrière Hospital (FR)
- Center for Pain and the Brain (US)
- Edelweiss Connect (Switzerland) (CH)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Circulation
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1161/circulationaha.125.076976
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 24.20